Vincent C O Njar

List of Publications by Year
in descending order

86	8,917	117571 34	54882 84
papers	citations	h-index	g-index

92	92	92	17424
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transcriptome profiling reveals that VNPP433â€3Î², the lead nextâ€generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelialâ€“mesenchymal transition and stem cell markers. Molecular Carcinogenesis, 2022, 61, 643-654.	1.3	25
2	Novel deuterated Mnk1/2 protein degrader VNLG-152R analogs: Synthesis, In vitro Anti-TNBC activities and pharmacokinetics in mice. European Journal of Medicinal Chemistry, 2022, 238, 114441.	2.6	7
3	Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3Î². Steroids, 2022, 185, 109062.	0.8	4
4	Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 2020, 12, 3412.	1.7	3
5	Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3Î² Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. Cancers, 2019, 11, 1637.	1.7	20
6	The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. Cancers, 2019, 11, 299.	1.7	18
7	The retinamide <scp>VNLG</scp>â€152 inhibits <scp>fâ€AR</scp>/<scp>AR</scp>â€V7 and <scp>MNK</scp>â€“<scp>eIF</scp>4E signaling pathways to suppress <scp>EMT</scp> and castrationâ€resistant prostate cancer xenograft growth. FEBS Journal, 2018, 285, 1051-1063.	2.2	33
8	Targeting of protein translation as a new treatment paradigm for prostate cancer. Current Opinion in Oncology, 2017, 29, 210-220.	1.1	20
9	Letter to the editor. Expert Opinion on Therapeutic Targets, 2017, 21, 9-10.	1.5	1
10	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. Journal of Steroid Biochemistry and Molecular Biology, 2017, 166, 16-27.	1.2	35
11	Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget, 2017, 8, 52381-52402.	0.8	14
12	Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. Oncotarget, 2017, 8, 88501-88516.	0.8	10
13	Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy. Translational Cancer Research, 2017, 6, S1128-S1131.	0.4	1
14	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3Î²-Imidazole Carbamate. ACS Medicinal Chemistry Letters, 2016, 7, 708-713.	1.3	19
15	Improved Procedures for Gram-Scale Synthesis of Galeterone 3Î²-Imidazole and Galeterone 3Î²-Pyridine Methoxylate, Potent Androgen Receptor/Mnk Degrading Agents. Organic Process Research and Development, 2016, 20, 1654-1661.	1.3	8
16	Galeterone and <scp>VNPT</scp>55 disrupt Mnkâ€<scp>eIF</scp>4E to inhibit prostate cancer cell migration and invasion. FEBS Journal, 2016, 283, 3898-3918.	2.2	39
17	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
18	Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC.. Journal of Clinical Oncology, 2016, 34, e14092-e14092.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget, 2015, 6, 3195-3210.	0.8	25
20	Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics, 2015, 14, 1777-1793.	1.9	42
21	Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer. Journal of Medicinal Chemistry, 2015, 58, 2077-2087.	2.9	164
22	Novel C-4 Heteroaryl 13-cis-Retinamide Mnk/AR Degrading Agents Inhibit Cell Proliferation and Migration and Induce Apoptosis in Human Breast and Prostate Cancer Cells and Suppress Growth of MDA-MB-231 Human Breast and CWR22Rv1 Human Prostate Tumor Xenografts in Mice. Journal of Medicinal Chemistry, 2015, 58, 1900-1914.	2.9	31
23	Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenograftsin vivo. Oncotarget, 2015, 6, 27440-27460.	0.8	91
24	Abstract 1764: Galeterone and its novel analogs induce profound anti-cancer activities in human pancreatic cancer cell lines: Implications for pancreatic cancer therapy. , 2015, , .		1
25	VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. European Journal of Pharmacology, 2014, 734, 98-104.	1.7	6
26	First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget, 2014, 5, 530-543.	0.8	52
27	Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry, 2013, 56, 4880-4898.	2.9	92
28	The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis, 2013, 34, 199-210.	1.3	41
29	Autophagy Inhibition Synergistically Enhances Anticancer Efficacy of RAMBA, VN/12-1 in SKBR-3 Cells, and Tumor Xenografts. Molecular Cancer Therapeutics, 2012, 11, 898-908.	1.9	18
30	A new simple and high-yield synthesis of 5Î±-dihydrotestosterone (DHT), a potent androgen receptor agonist. Steroids, 2012, 77, 1530-1534.	0.8	11
31	Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemotherapy and Pharmacology, 2012, 70, 339-344.	1.1	4
32	Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Research and Treatment, 2012, 133, 137-144.	1.1	4
33	First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): Identification of novel RAMBA scaffolds. European Journal of Medicinal Chemistry, 2012, 47, 412-423.	2.6	15
34	CYP17 inhibitors for prostate cancer therapy. Journal of Steroid Biochemistry and Molecular Biology, 2011, 125, 23-31.	1.2	177
35	Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids, 2011, 76, 1268-1279.	0.8	67
36	Prostate Cancer: Current and Emerging Therapies. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
37	New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer. Prostate Cancer, 2011, 2011, 1-13.	0.4	9
38	Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Medicinal Chemistry, 2010, 2, 667-680.	1.1	33
39	The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 53-63.	0.8	28
40	4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 7122-7131.	2.9	50
41	Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opinion on Drug Discovery, 2009, 4, 1099-1111.	2.5	164
42	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorganic and Medicinal Chemistry, 2008, 16, 3352-3360.	1.4	48
43	Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic and Medicinal Chemistry, 2008, 16, 3519-3529.	1.4	27
44	Synthesis of novel C17 steroidal carbamates. Steroids, 2008, 73, 1217-1227.	0.8	25
45	Design, Synthesis, and Evaluation of Novel Mutual Prodrugs (Hybrid Drugs) of All-trans-Retinoic Acid and Histone Deacetylase Inhibitors with Enhanced Anticancer Activities in Breast and Prostate Cancer Cells in Vitro. Journal of Medicinal Chemistry, 2008, 51, 3895-3904.	2.9	37
46	Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics, 2008, 7, 121-132.	1.9	55
47	17Î±-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Molecular Cancer Therapeutics, 2008, 7, 2828-2836.	1.9	64
48	Androgen receptor inactivation contributes to antitumor efficacy of 17Î±-hydroxylase/17,20-lyase inhibitor 3Î²-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics, 2008, 7, 2348-2357.	1.9	137
49	Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at Iα7* Nicotinic Receptors. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 48-58.	1.3	77
50	Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids, 2007, 72, 939-948.	0.8	42
51	First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents. Bioorganic and Medicinal Chemistry, 2007, 15, 3413-3421.	1.4	27
52	Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorganic and Medicinal Chemistry, 2007, 15, 5047-5060.	1.4	228
53	Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemotherapy and Pharmacology, 2007, 60, 899-905.	1.1	8
54	Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorganic and Medicinal Chemistry, 2006, 14, 4323-4340.	1.4	132

#	ARTICLE	IF	CITATIONS
55	Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 2006, 10, 309-319.	7.7	325
56	Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells. Cancer Research, 2006, 66, 11485-11493.	0.4	27
57	Retinoids in Clinical Use. Medicinal Chemistry, 2006, 2, 431-438.	0.7	12
58	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:Â Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model. Journal of Medicinal Chemistry, 2005, 48, 2972-2984.	2.9	228
59	A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or in Combination with Retinoids on Proliferation of Human Prostate Cancer Cells. Journal of Medicinal Chemistry, 2005, 48, 5047-5051.	2.9	98
60	Novel Retinoic Acid Metabolism Blocking Agents Endowed with Multiple Biological Activities Are Efficient Growth Inhibitors of Human Breast and Prostate Cancer Cells in Vitro and a Human Breast Tumor Xenograft in Nude Mice. Journal of Medicinal Chemistry, 2004, 47, 6716-6729.	2.9	48
61	Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 155-165.	1.2	23
62	Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 810, 203-208.	1.2	5
63	Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 810, 203-208.	1.2	6
64	Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice. Cancer Chemotherapy and Pharmacology, 2003, 51, 519-524.	1.1	4
65	Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy. Journal of Medicinal Chemistry, 2003, 46, 2345-2351.	2.9	86
66	Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1905-1908.	1.0	25
67	High-Yield Synthesis of Novel Imidazoles and Triazoles from Alcohols and Phenols. Synthesis, 2000, 2000, 2019-2028.	1.2	33
68	Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. Journal of Steroid Biochemistry and Molecular Biology, 2000, 75, 1-10.	1.2	67
69	Aromatase inhibitors and their application in breast cancer treatmentÃ¢Â‹Â†. Steroids, 2000, 65, 171-179.	0.8	105
70	Cytochrome P450c17-ExpressingEscherichia colias a First-Step Screening System for 17Î±-Hydroxylase-C17,20-lyase Inhibitors. Analytical Biochemistry, 1999, 267, 319-330.	1.1	28
71	Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors. Drugs, 1999, 58, 233-255.	4.9	75
72	Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17Î±-Hydroxylase-C17,20-lyase (P45017Î±):Â Potential Agents for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry, 1998, 41, 902-912.	2.9	117

#	ARTICLE	IF	CITATIONS
73	Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. Journal of Steroid Biochemistry and Molecular Biology, 1998, 66, 1-10.	1.2	86
74	Synthesis of novel 21-trifluoropregnane steroids: Inhibitors of 17Î±-hydroxylase/17,20-lyase (17Î±-lyase). Steroids, 1997, 62, 468-473.	0.8	17
75	Synthesis of 10Î²-(1â€²-azirinyl)estr-4-en-3,17-dione as an aromatase inhibitor. Steroids, 1996, 61, 138-143.	0.8	10
76	20-Amino and 20,21-aziridinyl pregnene steroids: Development of potent inhibitors of 17Î±-hydroxylase/C17,20-lyase (P450 17). Bioorganic and Medicinal Chemistry, 1996, 4, 1447-1453.	1.4	42
77	Nucleophilic vinylic â€œaddition-eliminationâ€•substitution reaction of 3Î²-acetoxy-17-chloro-16-formylandrosta-5,16-diene: A novel and general route to 17-substituted steroids. Part 1 - synthesis of novel 17-azolyl-Î”16 steroids; inhibitors of 17Î±-hydroxylase/17, 20-lyase (17Î±-lyase). Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2777-2782.	1.0	40
78	Methyl Angolensate: The Antiulcer Agent of the Stem Bark ofEntandrophragma angolense. Planta Medica, 1995, 61, 91-92.	0.7	70
79	Antifertility Activity ofQuassia amara: Quassin Inhibits the Steroidogenesis in Rat Leydig CellsIn Vitro. Planta Medica, 1995, 61, 180-182.	0.7	34
80	Evaluation of 6,7-Aziridinyl Steroids and Related Compounds as Inhibitors of Aromatase (P-450arom). Journal of Enzyme Inhibition and Medicinal Chemistry, 1995, 9, 195-202.	0.5	9
81	Mechanistic studies on aromatase and related Cî—¸C bond cleaving P-450 enzymes. Journal of Steroid Biochemistry and Molecular Biology, 1993, 44, 375-387.	1.2	188
82	2-Methoxycanthin-6-one: A New Alkaloid from the Stem Wood ofQuassia amara. Planta Medica, 1993, 59, 259-261.	0.7	32
83	Synthesis of 6-hydroximino-3-oxo steroids, a new class of aromatase inhibitor. Journal of the Chemical Society Perkin Transactions 1, 1992, , 585.	0.9	32
84	Synthesis of C-2, 3, 17 and 19-oxygenated androgens. The Journal of Steroid Biochemistry, 1988, 29, 353-359.	1.3	3
85	Concerning the pathway from 19-oxoandrost-4-ene-3,17-dione to estrone. Steroids, 1987, 50, 347-362.	0.8	10
86	Development of Benzimidazole Compounds for Cancer Therapy. , 0, , .		8